Phase III dosing defined for lixivaptan in autosomal dominant polycystic kidney disease Nov. 20, 2019
First placebo-controlled trial in renal scleroderma shows positive results for zibotentan Nov. 19, 2019
Sparsentan does not appear to have a negative effect on quality of life in FSGS patients Nov. 18, 2019
Results from SILK cohort evaluating tesevatinib in ADPKD patients presented at Kidney Week Nov. 15, 2019
Phase III portion of CARDINAL study of bardoxolone in Alport syndrome meets primary endpoint Nov. 12, 2019
RSS